Diagnos Laboratorium Utama PT Tbk (DGNS) - Total Liabilities
Based on the latest financial reports, Diagnos Laboratorium Utama PT Tbk (DGNS) has total liabilities worth Rp110.07 Billion IDR (≈ $6.45 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Diagnos Laboratorium Utama PT Tbk - Total Liabilities Trend (2017–2024)
This chart illustrates how Diagnos Laboratorium Utama PT Tbk's total liabilities have evolved over time, based on quarterly financial data. See Diagnos Laboratorium Utama PT Tbk (DGNS) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Diagnos Laboratorium Utama PT Tbk Competitors by Total Liabilities
The table below lists competitors of Diagnos Laboratorium Utama PT Tbk ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Telcon Inc
KQ:200230
|
Korea | ₩47.85 Billion |
|
Multi Indocitra Tbk
JK:MICE
|
Indonesia | Rp517.97 Billion |
|
Holista Colltech Ltd
AU:HCT
|
Australia | AU$6.29 Million |
|
Barrel Co. Ltd
KQ:267790
|
Korea | ₩32.33 Billion |
|
Alpha Microelectronics
TWO:8024
|
Taiwan | NT$35.14 Million |
|
I Synergy Group Ltd
AU:IS3
|
Australia | AU$1.63 Million |
|
Alliance Nickel Ltd
AU:AXN
|
Australia | AU$5.84 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Diagnos Laboratorium Utama PT Tbk's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DGNS stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Diagnos Laboratorium Utama PT Tbk's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Diagnos Laboratorium Utama PT Tbk (2017–2024)
The table below shows the annual total liabilities of Diagnos Laboratorium Utama PT Tbk from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rp103.89 Billion ≈ $6.09 Million |
+36.91% |
| 2023-12-31 | Rp75.88 Billion ≈ $4.45 Million |
+157.17% |
| 2022-12-31 | Rp29.51 Billion ≈ $1.73 Million |
-26.57% |
| 2021-12-31 | Rp40.18 Billion ≈ $2.35 Million |
+19.92% |
| 2020-12-31 | Rp33.51 Billion ≈ $1.96 Million |
+162.55% |
| 2019-12-31 | Rp12.76 Billion ≈ $747.85K |
+14.23% |
| 2018-12-31 | Rp11.17 Billion ≈ $654.69K |
+112.02% |
| 2017-12-31 | Rp5.27 Billion ≈ $308.79K |
-- |
About Diagnos Laboratorium Utama PT Tbk
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want t… Read more